Skip to search formSkip to main contentSkip to account menu

lumretuzumab

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

RG7116

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor… 
2018
2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic…
SummaryPurpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER… 
2018
2018
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and…
PurposeTo inform lumretuzumab and pertuzumab dose modifications in order to decrease the incidence, severity, and duration of the… 
2017
2017
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Purpose: We evaluated biodistribution and tumor targeting of 89Zr-lumretuzumab before and during treatment with lumretuzumab, a… 
2017
2017
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
Bidirectional cross talk between members of the human epidermal growth factor family of receptors (HER) and the estrogen receptor… 
2017
2017
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Purpose: This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized… 
2017
2017
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab
AbstractPurposeThis study aimed at evaluating if pharmacokinetic and pharmacodynamic data from the first few patients treated… 
2017
2017
Abstract P6-11-13: Phase Ib study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer
Background: Inhibition of HER2 and HER3 heterodimerisation is a novel treatment concept in HER2-”low” expressing breast cancer… 
2016
2016
89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.
11555Background: Lumretuzumab is a humanized, glycoengineered, monoclonal antibody targeting human epidermal growth factor… 
Highly Cited
2015
Highly Cited
2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Purpose: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)